Atrium Therapeutics, Inc. · NASDAQ:RNA
T. Rowe Price Associates Inc reported a 8.60% stake in Atrium Therapeutics, Inc. (Schedule 13G/A)
Event Jun 30, 2026 · Filed Aug 14, 2026
T. Rowe Price Associates Inc reported a 8.60% stake in Atrium Therapeutics, Inc., 1,472,984 shares, as a passive investor on Jun 30, 2026. Filed Aug 14, 2026 (Schedule 13G/A).
- Stake
- 8.60%
- Shares
- 1,472,984
- Intent
- Passive
- What changed
- Stake changed
The filing in full
| Holder | Stake | Shares |
|---|---|---|
| T. Rowe Price Associates, Inc. | 8.60% | 1,472,984 |
Source
Related
- Atrium Therapeutics, Inc.
- T. Rowe Price Associates Inc
- Atrium Therapeutics, Inc. shareholders
- Schedule 13G · T. Rowe Price Associates Inc · Apr 8, 2026
- Form 4 · Younis Husam · Sep 22, 2026
- Form 4 · Hughes Steven George · Sep 22, 2026
- Form 4 · Flanagan W. Michael · Sep 22, 2026
- Form 4 · Boyce Sarah · Sep 22, 2026
- Form 4 · Kenney Stephanie · Sep 22, 2026